Replies to post #550 on Rigel Pharmaceuticals Inc (RIGL)

[RNsidersbuying]

In April 2021, Rigel reported positive topline data from the multi-center, Phase 2 clinical trial evaluating the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19. The trial met its primary endpoint of safety, and showed broad and consistent improvement in numerous efficacy endpoints including mortality, ordinal scale assessment, and number of days in the ICU. The trial was conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and Inova Health System. The NHLBI is expected to publish a full analysis of the trial data in a peer-reviewed journal. Rigel is discussing these results with health authorities, including the U.S. Food and Drug Administration (FDA), and intends to apply for Emergency Use Authorization (EUA) for fostamatinib for the treatment of hospitalized COVID-19 patients.

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14927567&RcvdDate=5/5/2021&CoName=RIGEL%20PHARMACEUTICALS%20INC&FormType=8-K&View=html

https://www.outsourcedpharma.com/doc/navigating-the-fda-s-emergency-use-authorization-process-0001

of so many upcoming catalysts...as of right now this is my #1 position on this afterhours selloff